Document:

EXHIBIT 10.31

 

Second
Amendment to
Licensing
Agreement

 

This
Second Amendment
to Licensing
Agreement ("Second
Amendment")
is to
memorialize
the agreement
between PharmaCyte
Biotech,
Inc.,formerly
Nuvilex,
Inc. ("Licensee"),
and Austrianova
Singapore
Pte Ltd
("Licensor")
to amend,
effective as of
19 October
2015,
the Licensing
Agreement
between the
Parties dated
as of 1 December
2014 ("Licensing
Agreement")
as set forth below
. Defined
terms in
the Licensing
Agreement have
the same meaning
as the terms in this
Second Amendment.

 

	 	A.	The
Parties entered into
the Licensing
Agreement
to, among
other things,
provide
Licensee
with an exclusive
worldwide license
to use
the Cell-in-a-Box®
Trademark
and its
Associated
Technology
with genetically
modified
non-stem
cell lines
specifically
designed to
activate
members
of the Cannabinoid
family of molecules
to: (i)
conduct research;
(ii) have made by
Licensor; (iii)
use in preclinical
studies and
clinical trials;
(iv) obtain
marketing approval;
(v) and market
and sell products
and treatments
utilizing
the Cell-in-a-Box®
Trademark
and its
Associated Technology
world-wide;

 

	 	B.	The
Licensing
Agreement
provides Licensee
shall pay Licensor
an initial
payment
("Upfront
Payment")
of Two Million
Dollars US (USD
$2,000,000.00.
It further
provides that
Licensee shall
make periodic
monthly
partial payments
of the Upfront
Payment in amounts
to be agreed
upon between
the Parties
prior to
each such
payment
being made;
provided,
however
the Upfront
Payment
shall
be paid
in full by
no later
than 30 June
2015 ;

 

 

		C.	Effective
as of 30 June
2015, the Parties
extended the
date by which
the Upfront
Payment must be made
by Licensee
to 31 December
2015;
and

 

		D.	The
Parties desire
to further
extend the date
by which the
Upfront Payment
must be
made by Licensee to 30 June
2016.

 

NOW,
THEREFORE, for good
and valuable
consideration,
the receipt
and sufficiency
of which are
hereby acknowledged
by the
Parties,
the Research
Agreement is hereby
amended as follows:

 

1
.. Section
2.2 of the
Licensing
Agreement
shall
be deleted
and the
following inserted in
its place: "Subject
to the terms
of this
Agreement,
Licensee
shall pay
Licensor
an initial
payment
("Upfront
Payment")
of Two Million Dollars
US (USD
$2,000,000.00).
Licensee
shall make
periodic
monthly
partial payments of the
Upfront
Payment in
amounts
to be agreed upon
between the
Parties prior
to each such
payment being
made: provided,
however,
the Upfront
Payment shall
be paid in full by
no later
than 30 June
2016."

 

2.
Section 8.1.2.
of the Licensing
Agreement shall
be deleted
and the following
inserted
in its place:
"Similarly,
the License
may be terminated
and all rights
shall revert
to Licensor
if any of the
following
events
do not occur within
the timeframe
set forth in this Agreement
provided that
Licensor
gives Licensee
thirty (30) days'
notice
prior to the
effective
date of termination and
Licensee fails
to cure
the following
events
during
the thirty
(30) day period:
(i) if
Licensee
fails
to pay in
full the
Upfront Payment
by 30 June
2016; (ii)
if Licensee
does not enter
into a research program
involving
the Scope
of the Agreement
within three (3) years
of the Effective
Date; or
(iii)
if Licensee does
not enter
clinical
trials or their
equivalent
for a Product
within
seven (7) years from the
Effective
Date."

 

3.
Except as provided in this Second Amendment,
all of the other provisions of the Licensing Agreement
shall remain in full force and effect.

 

IN
WITNESS WHEREOF, each Party has
executed this First Amendment by
its duly authorized
representative as of the date first written above.

 

	PharmaCyte Biotech, Inc.	Austrianova
Singapore Pte Ltd
	 	 
	/s/ Kenneth L. Waggoner               	/s/ Brian Salmons              
	By: Dr. Kenneth L. Waggoner

                                    Title:
Chief Executive Officer

                                    
	By:

        Title:
	Dr. Brian Salmons
 Chief
Executive OfficerEXHIBIT 10.36

 

 

 

 

 

 

 

20 April 2016

 

 

 

Kenneth L. Waggoner

Chief Executive Officer and Director

Pharmacyte
Biotech Australia Pty Ltd

Level 15

300 Queen Street

Brisbane, QLD 4001

Australia

By
email: kwaggoner@PharmaCyte.com

 

RE: VARIATION TO LICENCE AGREEMENT DATED 10
OCTOBER 2014

 

Dear Ken,

 

We refer to recent discussions
regarding the need to clarify several terms and correct the named Licensee in the License Agreement between University of Technology,
Sydney and Pharmacyte Biotech Australia Pyt Ltd, formerly Nuvilex Australia Pty Ltd, made on 10 October 2014 ("License Agreement").

 

We confirm our agreement to vary the License
Agreement as follows:

 

		1.	At Item 2 of the Reference Schedule to replace the former name of
the Licensee "Nuvilex Australia Pty Ltd" with its new name "Pharmacyte Biotech Australia Pty Ltd" and including
the Australian Buisness Number after the name of the Licensee and to include the Australian Business Number (ABN 89 600 316 621)
after the name of the Licensee.	 
	 	 	 	 
		2.	At Item 8 of the Reference Schedule in the column
                    next to the words "Patent Administration Fee", the new wording to replace the current wording to
                    be, "15% on all Patent Costs paid by University to prosecute and maintain patents related to Licensed
                    Intellectual Property".	 
	 	 	 	 
		3.	The "Licensee" (page 4) replace the former name "Nuvilex
Australia Pty Ltd" with the new name "Pharmacyte Biotech Australia Pty Ltd" and replace Australian Company Number
(ACN 600 316 621) with the Australian Business Number (ABN 89 600 316 621).	 
	 	 	 	 
		4.	Insert a new definition "Patent Costs means any and all official
fees from any patent administering office or bureau, any and all attorney fees charged in relation to the prosecution of any Patent
in any jurisdiction, and any taxes or charges incurred or included in any invoice received by the Universtiy in relation to the
Licensed Intellectual Property".	 
	 	 	 	 
		5.	The following wording will replace the current wording of Clause 6.4. "Subject to Clause 6.5,
the Licensee will decide which patents shall be maintained and will pay the University a Patent Administration Fee (Item 8) and
all Patent Costs to administer the Intellectual Property on behalf of the Licensee."	 

 

 

 

    	 	1	 

     

    

 

In all
other respects we confirm the terms
and conditions
of the Licnese Agreement.

 

In accordance
with clause 18.8 of the Licence Agreement,
your signature below will constitute written confirmation
of this variation to the Licence Agreement dated 13 October 2014.

 

 

 

 

 

    	 	2EXHIBIT
10.37

 

First Amendment
to Licensing Agreement

 

This First Amendment to
Licensing Agreement ("First Amendment") is to memorialize the agreement between PharmaCyte Biotech, Inc.,
formerly Nuvilex, Inc. ("Licensee"), and Austrianova Singapore Pte Ltd ("Licensor”)
to amend, effective as of 24 June 2016,
the Licensing Agreement between the parties entered into as of June 25th,
2013 ("Licensing Agreement") as follows.

 

	 	A.	The parties entered
into the Licensing Agreement to provide Licensee with an exclusive worldwide license to use the Cell-in-a-Box® Trademark and
its Associated Technology with genetically modified non-stem cell lines and IPS stem cells specifically designed to produce insulin
or other critical components for the treatment of diabetes to research, have made by Licensor, use in clinical trial, obtain market
approval, market and sell products and treatments utilizing the Cell-in-a-Box® Trademark and its Associated Technology world-wide;

 

	 	B.	Section 8.1.2.1. of the Licensing Agreement provides that if
Licensee does not enter into a research program with the technology in the scope of the license granted in the Licensing
Agreement involving European academic university partners providing a total funding equal to or greater than US $400,000.00
within three year of the effective date of the Licensing Agreement, Licensor has the right to terminate the Licensing Agreement
on the condition that Licensor provide Licensee 30 days' notice
and the opportunity to cure Licensee's failure to meet this milestone event; and

 

	 	C.	The Parties desire
to amend the provisions of Section 8.1.2.1. to expand the scope
of the research program to include countries world-wide and not require the research program be limited to academic university
partners.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the
Parties, the Research Agreement is hereby amended as follows:

 

1.  
Section 8.1.2.1. of the Licensing Agreement shall be deleted
and the following inserted in its place: "If LICENSEE does not enter into a research program with the technology in the scope
of the License providing a total funding equal to or greater than Four Hundred Thousand Dollars US (US $400,000.00)
within three (3) years of the Effective Date; or"

 

2.  
Except as provided in this First Amendment, all of the other provisions of the Licensing Agreement shall remain in full
force and effect.

 

IN
WITNESS WHEREOF, each party to the Licensing Agreement has executed this First Amendment by its duly authorized representative
as of the date first written above.

 

	PharmaCyte Biotech, Inc.	Austrianova
Singapore Pte Ltd
	 	 
	/s/ Kenneth L. Waggoner               	/s/ Brian Salmons              
	By: Dr. Kenneth L. Waggoner

                                    Title:
Chief Executive Officer

                                    
	By:

        Title:
	Dr. Brian Salmons
 Chief
Executive OfficerEXHIBIT 10.38

 

 

BINDING MEMORANDUM OF UNDERSTANDING

 

This Binding Memorandum of Understanding (“MOU”)
is effective as of 28 July 2016 (“Effective Date”) and entered into by and between PharmaCyte Biotech, Inc.(“PharmaCyte”),
a Nevada corporation with its principal place of business at 12510 Prosperity Drive, Suite 310, Silver Spring, Maryland 20904
USA, and Austrianova Singapore Pte Ltd (“Austrianova”), a Singapore corporation, with its principal place of
business at 3 Biopolis Way #05-19, Synapase, Singapore, 138668. PharmaCyte and Austrianova are referred to in this MOU each as
a “Party” and collectively as the “Parties.”

 

RECITALS

 

A.          The Parties desire to enter into a relationship pursuant to which they will, together with one or more third parties, develop,
assess in clinical trials and manufacture and market various products for the treatment of cancer (“Products”)
in the Field (defined below) that utilize the cytochrome P450-based Technology (defined below). Except as otherwise provided in
this MOU, defined terms in the Third Addendum (defined below) and the Clarification Agreement (defined below) shall have the same
meaning in this MOU;

 

B.           The Parties desire to have the relationship described in this MOU apply only in the “Territories” (defined below);

 

C.           Austrianova has offered to actively work to seek an investment partner or partners (“Investment Partner”) who
will finance clinical trials and further develop Products in the Field, including the cost of Product manufacturing and marketing
approval from the country or countries in which each Product is approved in exchange for an agreed upon percentage of Product Revenue
(defined below). For their contribution to the relationship, the Parties desire each Party to receive an equal share of any Product
Revenue; and

 

D.           It is the intent of the Parties that a separate binding written agreement (“Agreement”) will be negotiated in
good faith with regard to each Party’s obligations and responsibilities to implement the intent of this MOU.

 

E.            The Parties are signatories to a Manufacturing Framework Agreement entered into as of the 20th day of March 2014, pursuant
to which the production of Phase 2 clinical trial material utilizing the P450 Technology will be supplied by Austrianova to PharmaCyte
for a Phase 2 clinical trial to be conducted by PharmaCyte and which will take place in the United States with study sites in Europe.
The Parties recognize the need to negotiate a new Manufacturing Framework Agreement pursuant to which the production of Phase 3
clinical trial material utilizing the P450 Technology will be supplied by Austrianova to PharmaCyte for PharmaCyte to conduct a
Phase 3 clinical trial in the United States with study sites in Europe.

 

    	 	1	 

     

    

 

AGREEMENT

 

1.          Defined Terms. The Agreement shall include, among others, the following defined terms:

 

(a)          “Affiliate” shall mean, with respect to the Parties, any corporation or other business entity controlling,
controlled by or under common control with that party. The term “controlling,” with correlative meanings for
the terms “controlled by” and “under common control with” as used in this definition means either: (i)
possession of the direct or the indirect ownership of more than fifty percent (50%) of the voting or income interest of the applicable
corporation or other business entity; or (ii) the ability, by contract or otherwise, to control the management of the applicable
corporation or other business entity.

 

(b)          “Active Pharmaceutical Ingredient” shall mean the genetically modified HEK293 cells overexpressing the cytochrome
P450 2B1 gene that have been produced according to cGMP standards.

 

(c)          “Associated Technology” shall mean technologies owned by SG Austria or an Affiliate of Austrianova and marketed
by Austrianova under the Cell-in-a-Box® registered trademark which enables encapsulation of live eukaryotic cells
placed in a polymer where one constituent of the encapsulation material is cellulose sulphate or a derivative thereof and shall
include any derivative or further development of these technologies.

 

(d)          “Cell-in-a-Box® Trademark and its Associated Technology” refers to United States registered
trademark No. 85307295 that is owned by SG Austria and the Associated Technology.

 

(e)          “Confidential Information” shall mean any and all technical or commercial information that is provided by
one Party or its Affiliate to the other Party or its Affiliate after the Effective Date that is of a confidential nature or is
received in circumstances in which the receiving Party knows or should know that the information is confidential, including, without
limitation, data, know-how, formulae, processes, designs, photographs, drawings, specifications, software programs and samples
of any other material bearing or incorporating information relating to the business of either Party, whether or not such information
is marked as “Confidential.”

 

(f)           “Field” shall mean the use of the P450 Technology specifically designed for the treatment of cancer.

 

    	 	2	 

     

    

 

(g)          “P450 Technology” shall mean the Active Pharmaceutical Ingredient encapsulated using the Cell-in-a-Box®
Trademark and its Associated Technology.

 

(h)          “Product Revenue” shall mean any net revenue generated from the sale of any Products in the Field and within
the Territories (defined below). In calculating “Product Revenue,” any royalty or other fees PharmaCyte is currently
contractually obligated to pay Bavarian Nordic A/S and GSF – Forschungszentrum für Umwelt u. Gesundheit GmbH (“Bavarian
Nordic/GSF”) under PharmaCyte’s License Agreement with Bavarian Nordic/GSF, as amended, will be taken into account
in calculating Product Revenue.

 

(i)           “Territories” shall mean countries in which there is no patent protection arising from granted or pending
patents, or extensions thereof, based on the family of patents originating from the applications WO 1997001357 A1 and WO 1997035994
A3 filed by Bavarian Nordic/GSF.

 

2.          Grant
of License by PharmaCyte; Active Pharmaceutical Ingredient. PharmaCyte will grant an exclusive royalty-free sub-license to
the parties to the Third Party Agreement (defined below) under the license PharmaCyte obtained from Bavarian Nordic/GSF or otherwise
to use and commercialize the Active Pharmaceutical Ingredient to carry out the provisions of the Third Party Agreement. PharmaCyte
will also provide the Active Pharmaceutical Ingredient free of charge in the form of vials of a Working Cell Bank to the extent
necessary to produce a Product in the Field. The
grant of this royalty-free sub-license and the free use of the Active Pharmaceutical Ingredient by PharmaCyte shall in no way conflict
with the licensed rights of PharmaCyte to use the “Associated Technology” and the “Cell-in-a-Box®
Trademark and its Associated Technology” for use in the Field, as set forth the Third Addendum to Asset Purchase Agreement
between SG Austria and PharmaCyte effective as of June 25, 2013 (“Third Addendum”), as amended by the Clarification
Agreement to Third Addendum to Asset Purchase Agreement between SG Austria and PharmaCyte effective as of June 25, 2013 (“Clarification
Agreement”). Nor shall a sublicense
fee or any other fee or royalty be charged by SG Austria for the grant of such a sub-license or the sale of any Product in the
Territories under the Third Addendum and the Clarification Agreement.

 

3.          Grant of License by Austrianova. Austrianova shall grant the parties to the Third Party Agreement (defined below) an exclusive
royalty-free license to use the Cell-in-a-Box® Trademark and its Associated Technology for Products in the Field
sold within the Territories.

 

4.          Joint Venture/Framework/Revenue Sharing/Cooperation Agreement. The Parties and the Investment Partner or Partners shall enter
into a Joint Venture, Framework, Revenue Sharing or Cooperation Agreement (“Third Party Agreement”) to carry
out the purposes of this MOU with respect to the sale of Products in the Field within the Territories, with terms and conditions
that are reasonable and customary in an agreement of this kind. For their respective contributions to the Third Party Agreement,
the Parties will work with each Investment Partner with the goal that the Parties and the Investment Partner will each receive
33.3% of any Product Revenue; provided, however, any other Product Revenue sharing percentage agreed to by the Parties in order
to consummate a transaction with an Investment Partner will be acceptable.

 

    	 	3	 

     

    

 

5.          Efforts to Secure Partner. Austrianova will actively seek an Investment Partner who will become a party to the Third Party
Agreement and who will finance clinical trials and further develop of Products in the Field for sale within the Territories, as
determined by the Parties, including the cost of Product manufacturing and marketing approval from the country or countries in
which each Product is approved.

 

6.          Clinical Trials and Disclosure of Results of Clinical Trials. Except as otherwise required by law, the commencement of any
clinical trial or any public disclosure thereof pursuant to the Agreement shall not take place without the prior written consent
of Austrianova and PharmaCyte. Except as otherwise required by law, the results of any clinical trial shall not be made public
or reported to any regulatory agency without the prior written consent of Austrianova and PharmaCyte.

 

7.          Manufacture Set-Up Fee for Phase 1 and Phase 2 Clinical Trials. The manufacture set-up fee for Phase 1 and Phase 2 clinical
trials, if any, shall be the responsibility of Austrianova to the extent it is not paid for by the Investment Partner.

 

8.          New Manufacturing Framework Agreement for Phase 3 Material. During the third quarter of 2016 the Parties agree to commence
negotiating in good faith a new Manufacturing Framework Agreement pursuant to which Austrianova will provide PharmaCyte with Phase
3 clinical material utilizing the P450 Technology to conduct a Phase 3 clinical trial in the United States with study sites in
Europe.

 

9.          Joint Development Committee. The Parties and the Investment Partner will establish a Joint Development Committee (“JDC”)
that will oversee the strategy for and coordinate and implement: (i) conducting any clinical trials of the Product needed to obtain
regulatory approvals of the Product in the Field in the Territory; (ii) filing applications for and maintaining such regulatory
approvals in the Territory; and (iii) conducting any clinical trials of the Product in the Field needed to maintain regulatory
approval in the Territory as well as any other clinical trials of the Product in the Field (including investigator initiated trials)
conducted for a purpose other than to maintain regulatory approvals in the Territory.  Additional details about the composition
of the JDC, frequency of meetings and scope of responsibility will be described in the Third Party Agreement.

 

10.          Conditions to the MOU. The consummation of the transactions contemplated by this MOU shall
be subject to satisfaction of various customary conditions, including, without limitation, the following by each of the Parties:

 

    	 	4	 

     

    

 

(a)          approve this MOU by the Board of Directors or other authorized management of the Parties;

 

(b)          maintain their respective business operations in the ordinary course and prevent any material adverse change in the physical
or operational condition of their business operations subsequent to the execution of this MOU; and

 

(c)          secure any required governmental or third-party approvals, waivers or consents to consummate the transactions contemplated
by this MOU.

 

11.          Miscellaneous.

 

(a)          Conduct and Legal Compliance. The Parties shall comply with all United States and other
country laws and regulations applicable to the performance of their obligations under this MOU and the Agreement, including, but
not limited to, the provisions of the United States Foreign Corrupt Practices Act. Neither Party shall pay, promise to pay or authorize
the payment of money or anything of value, directly or indirectly, to any person (whether a governmental official or a private
individual) for the purpose of illegally or improperly inducing or attempting to induce any foreign official or political party
or official thereof to make a buying decision or illegally or improperly assist either Party in obtaining or retaining business,
or to take any other action favorable to the Parties in connection with any proposed transaction between the Parties or a third
party.

 

(b)          Choice of Laws. This MOU shall be construed according to the laws of England.

 

(c)          Mediation. In the event of any dispute arising between the Parties arising out of or related to the MOU (“Dispute”),
the Parties shall use their best endeavours to settle amicably such Dispute by consultation and negotiation. In the event the Parties
are not able to resolve any Dispute, the Parties shall first to try in good faith to settle the Dispute by mediation, the cost
of which shall be assumed equally by both Parties. Either Party may initiate the mediation by providing a written request to the
other Party.

 

(d)          Arbitration. Any Dispute which cannot be resolved by consultation, negotiation and mediation between the Parties shall, within
ninety (90) days of commencement of the discussions under Section 10. (c), be referred to and finally resolved by arbitration in
London, England in accordance with the Arbitration Rules of the London International Arbitration Centre for which rules are deemed
to be incorporated by reference to this Section 10 (d). The language of the arbitration shall be English. Any award made under
this Section 10. (d) shall be final and binding upon the Parties. Judgment on such award may be entered by any court or tribunal
having jurisdiction thereof.

 

(e)          Binding Agreement; Modification. This MOU constitutes a binding agreement between the Parties, subject to further negotiations
of the final terms and conditions that will be incorporated into the Agreement. The Parties agree to negotiate in good faith to
carry out the purpose and intent of this MOU. No amendment or modification or waiver of any provisions of this MOU shall be effective
unless made in writing and signed by a duly authorized officer of each Party.

 

    	 	5	 

     

    

 

(f)          Successors and Assigns. This MOU shall be binding upon the successors and assigns of the Parties. Austrianova shall undertake
to impose the obligations under this MOU upon its legal successors and assigns. PharmaCyte shall undertake to impose the obligations
under this MOU upon its legal successors or assigns. Except as otherwise expressly provided for in this MOU, neither Party shall
be entitled to assign this MOU or any rights hereunder to any third party without the prior written consent of the other Party,
except that a Party may assign this MOU to its successor in interest pursuant to a merger, acquisition or sale of all or substantially
all of its assets. 

 

(g)          Force Majeure. Both Parties shall be excused from the performance of their obligations under this MOU to the extent that such
performance is prevented by force majeure and the non-performing Party promptly provides notice of the force majeure
event to the other Party. If the force majeure in question continues for a period in excess of three (3) months, the Parties
shall enter into bona fide discussion with a view to agreeing upon such alternative arrangements as may be fair and reasonable.
If the Parties cannot agree such alternative arrangement, then either Party shall be entitled to terminate this MOU by thirty (30)
days’ “Notice” to the other Party prior to the effective date of the termination.

 

(h)          Notice. No notice or other communication from one Party to the other (“Notice”) shall have any validity
unless made in writing by or on behalf of the Party concerned. Any Notice that is to be given by either Party to the other may
be given by letter, facsimile transmission or electronic mail. Such letters shall be delivered by hand or sent prepaid by certified
mail, addressed to the other Party at the address given above as the registered address of each Party, with receipted recorded
delivery. Notice shall be considered received upon receipt of any such letter, facsimile transmission or electronic mail.

 

(i)          Press Releases and Media Statements. No press or media statement may be released by either Party to this MOU with regard to
the existence of this MOU or the subject of this MOU without the express prior consent of the other Party as to content and as
to the nature and extent of the press or media statement.

 

(j)          No Drafting Inference. This MOU has been prepared jointly and shall not be strictly construed against either Party. Ambiguities,
if any, in this MOU shall not be construed against any Party regardless of which Party may be deemed to have authored the ambiguous
provision.

 

(k)          Invalidity of Certain Provisions. If any one or more of the provisions of this MOU are held to be invalid or unenforceable
by any court of competent jurisdiction from which no appeal can be or is taken, the provisions shall be considered severed from
this MOU and shall not serve to invalidate any remaining provisions of the MOU. The Parties shall make a good faith effort to replace
any invalid or unenforceable provision with a valid and enforceable provision such that the objectives contemplated by the Parties
when entering this MOU may be realized.

 

    	 	6	 

     

    

 

(l)          Enforcement or Waiver. Any delay in enforcing a Party’s right under this MOU or any waiver as to a particular default
or other matter shall not constitute a waiver of such Party’s right to the future enforcement of its rights under the MOU,
except only as to an express written and signed waiver as to a particular matter for particular period of time.

 

(m)          No Authority to Bind a Party. Nothing in this MOU shall be construed to give either Party the power or authority to act for,
bind or commit the other Party in any way. Nothing in this MOU shall be construed to create a partnership between the Parties,
principle-agent relationship or any other form of relationship between the Parties expects as specifically set forth in the Agreement.

 

(n)          Confidentiality of MOU. The Parties agree that, without the prior written consent of the other Party, which may be withheld
in such Party’s sole discretion, neither Party shall disclose any provision of this MOU, or its existence, to any third party
(subject to the other terms set forth herein).

 

(o)          Fees and Costs of MOU and Agreement. Each Party shall pay its own attorney's fees, costs and expenses incurred in connection
with this MOU and the Agreement.

 

(p)          Section Headings. Section headings are used
in this MOU for convenience only and are not to be considered in construing or interpreting this MOU.

 

(q)          Counterpart Signatures. The Third Addendum may be executed in two counterparts, each of which shall be an original and all
of which shall constitute together the same document.

 

IN WITNESS WHEREOF, the Parties have
executed this MOU as of the Effective Date.

 

 

	
        /s/ Dr. Brian Salmons

        Dr. Brian Salmons

        Chief Executive Officer

        SG Austria Pte Ltd
	
        /s/ Dr. Kenneth L. Waggoner

        Dr. Kenneth L. Waggoner

        Chief Executive Officer

        PharmaCyte Biotech, Inc.

 

    	 	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}]]